Lixte Biotechnology Holdings Inc. - LIXT Enterprise Value-to-Sales Ratio

Official company branding of lixte.com (LIXT)

Lixte Biotechnology is scaling combined oncology therapies through partnerships with global centers. This linear chart of the EV/Revenue ratio on GURU.Markets demonstrates business resilience, with the indicator standing at 0.00. The development of inhibitors for various tumors mitigates risks, although geopolitical tensions and sanctions are currently hindering reagent logistics and the execution of international clinical trials.

Lixte Biotechnology, Inc. (LIXT): Company Value to Revenue from 11/23/2025 to 07/06/2026

Lixte Biotechnology Holdings - analytical breakdowns and key metrics (LIXT)

Fundamental company valuation:LIXT, lixte.com
Manufactured products of Lixte Biotechnology Holdings Inc.

The EV/Sales metric determines the market value of a business relative to its revenue, excluding the impact of leverage to identify the net value of the generated cash flow. By analyzing the EV/Sales valuation chart on GURU.Markets, an investor can see the speculative value of Lixte Biotechnology (LIXT), which, at its current stage of R&D in oncotherapy, does not rely on commercial sales, turning the indicator into a reflection of expectations for future innovations.